Therapeutic trials for canine bladder cancer (NOT CURRENTLY RECRUITING)
Principal Investigator
Dr Shelly Vaden
Description
This study will investigate whether the administration of a dietary supplement slows the progression of canine bladder cancer (also known as transitional cell carcinoma/urothelial carcinoma, or TCC/UC) in dogs treated with standard of care therapy
Testing Requirements
Participants will be asked to:
– bring their dog for an initial clinical evaluation at NC State College of Veterinary Medicine (CVM)
– return to the CVM periodically for clinical re-evaluation of their dog (typically every 1-3 months)
– provide their dog with the supplied dietary supplement (or placebo), a once-daily tablet
– submit a urine sample from their dog to the study each month
– complete a short online questionnaire each month regarding their dog’s wellness
Enrollment Start
01/01/2022
Enrollment Finish
01/01/2025 (recruitment may be extended beyond this date)
Eligibility
– dogs must have received a diagnosis of urothelial carcinoma/bladder cancer within the previous three months
– dogs without a formal diagnosis but with a measurable bladder mass (detected by ultrasonography) may also be eligible
– dogs must not have received any cytotoxic chemotherapy or radiation treatment for their disease (treatment with a non-steroidal anti-inflammatory drug, or NSAID, is acceptable)
– dogs of any breed, sex or age are eligible
Study Benefits
The following are provided at no cost to the owner:
– monthly screening of their dog’s urine with the BRAF Mutation Detection Test
– clinical evaluation of their dog for the presence of urothelial carcinoma/bladder cancer
– standard of care treatment (which may include chemotherapy, typically mitoxantrone and/or piroxicam)
– a daily dietary supplement or placebo
– periodic clinical re-evaluation of their dog
Flyer
View this study recruitment flyer for more information
Contact
- Categories:
